1 | endpoint | 10,481 |
2 | end-point | 1,082 |
3 | care-based | 111 |
4 | aldosteronism | 78 |
5 | nonfunction | 20 |
6 | scale-international | 11 |
7 | care-relevant | 9 |
8 | tgcts | 7 |
9 | typus | 5 |
10 | care-delivered | 4 |
11 | e-scale | 4 |
12 | reattachments | 4 |
13 | aizawa | 3 |
14 | hiv-1-infection | 3 |
15 | nu-onset | 3 |
16 | se/sp | 3 |
17 | ser89 | 3 |
18 | 1hmrsi-dcemr | 2 |
19 | al-qadim | 2 |
20 | amine-specific | 2 |
21 | care-feasible | 2 |
22 | care–relevant | 2 |
23 | endpoint-the | 2 |
24 | gs-01-934 | 2 |
25 | heat/alkali | 2 |
26 | hemofiltration-hemodialysis | 2 |
27 | nonfunctionality | 2 |
28 | outcome-baseline-adjusted | 2 |
29 | outcome-the | 2 |
30 | outcomes-the | 2 |
31 | p-40 | 2 |
32 | pccc-pobh | 2 |
33 | siv-induced | 2 |
34 | udca+same | 2 |
35 | -spinal-epidural | 1 |
36 | 1.656 | 1 |
37 | 14mg/kg | 1 |
38 | 20-24°c | 1 |
39 | 205°c | 1 |
40 | 3.1mg/ml | 1 |
41 | 300μl/min | 1 |
42 | 32.10µg/ml | 1 |
43 | 40x/field | 1 |
44 | 47s | 1 |
45 | 48hpi | 1 |
46 | amine-nitro | 1 |
47 | aminocatalysts | 1 |
48 | anti-lipidemia | 1 |
49 | antibacterial-agent | 1 |
50 | au-onset | 1 |
51 | care-clinics | 1 |
52 | care-plus | 1 |
53 | care. | 1 |
54 | care.participants | 1 |
55 | care.subjects/methods | 1 |
56 | care/commercial | 1 |
57 | caregiver/parent | 1 |
58 | care—relevant | 1 |
59 | characteristics-relevance | 1 |
60 | cheiloplasties | 1 |
61 | derailments | 1 |
62 | dysmenorrhoea-ii | 1 |
63 | endocrine-therapy | 1 |
64 | endpoint-cardiac | 1 |
65 | endpoint-locoregional | 1 |
66 | epi-regimen | 1 |
67 | falcigers | 1 |
68 | heart-rate/accelerometry | 1 |
69 | heartburn/regurgitation/dyspepsia | 1 |
70 | hemipelvises | 1 |
71 | hgsil/carcinoma | 1 |
72 | hipertrigliceridemia | 1 |
73 | hyercholesterolaemia | 1 |
74 | hyperoxalurias | 1 |
75 | idh1/mgmt | 1 |
76 | interest-for | 1 |
77 | leuokocytes | 1 |
78 | lipodystrophy-a | 1 |
79 | malignancies.this | 1 |
80 | microfil | 1 |
81 | mid-distraction | 1 |
82 | mortality/esrd | 1 |
83 | motordisturbance | 1 |
84 | n=2215 | 1 |
85 | n=3226 | 1 |
86 | neurrorhaphy | 1 |
87 | oftacrolimus | 1 |
88 | oral/intranasal | 1 |
89 | osteoarthris | 1 |
90 | outcme | 1 |
91 | outcome-consistent | 1 |
92 | outcome-latch | 1 |
93 | outcome-measure | 1 |
94 | outcome-reduction | 1 |
95 | outcomes-wheezing | 1 |
96 | outcomes.very | 1 |
97 | outcomes/statistical | 1 |
98 | outcomesthere | 1 |
99 | pci-an | 1 |
100 | pci.further | 1 |
101 | photographer | 1 |
102 | production/respiration | 1 |
103 | protoalkaloid | 1 |
104 | protoalkaloidal | 1 |
105 | purpose—food | 1 |
106 | radiochemotherapy/surgery | 1 |
107 | rapid3-est | 1 |
108 | risk-relevant | 1 |
109 | rs2472304 | 1 |
110 | score≥210 | 1 |
111 | seromismatch | 1 |
112 | subjective/physiologic | 1 |
113 | treatment.small | 1 |
114 | trial-endpoints | 1 |
115 | vaccination.the | 1 |
116 | videoscoring | 1 |
117 | ~260k | 1 |
118 | α=0.10 | 1 |
119 | ≥26-week | 1 |
1 | -spinal-epidural | 1 |
2 | 1.656 | 1 |
3 | 14mg/kg | 1 |
4 | 1hmrsi-dcemr | 2 |
5 | 20-24°c | 1 |
6 | 205°c | 1 |
7 | 3.1mg/ml | 1 |
8 | 300μl/min | 1 |
9 | 32.10µg/ml | 1 |
10 | 40x/field | 1 |
11 | 47s | 1 |
12 | 48hpi | 1 |
13 | aizawa | 3 |
14 | al-qadim | 2 |
15 | aldosteronism | 78 |
16 | amine-nitro | 1 |
17 | amine-specific | 2 |
18 | aminocatalysts | 1 |
19 | anti-lipidemia | 1 |
20 | antibacterial-agent | 1 |
21 | au-onset | 1 |
22 | care-based | 111 |
23 | care-clinics | 1 |
24 | care-delivered | 4 |
25 | care-feasible | 2 |
26 | care-plus | 1 |
27 | care-relevant | 9 |
28 | care. | 1 |
29 | care.participants | 1 |
30 | care.subjects/methods | 1 |
31 | care/commercial | 1 |
32 | caregiver/parent | 1 |
33 | care–relevant | 2 |
34 | care—relevant | 1 |
35 | characteristics-relevance | 1 |
36 | cheiloplasties | 1 |
37 | derailments | 1 |
38 | dysmenorrhoea-ii | 1 |
39 | e-scale | 4 |
40 | end-point | 1,082 |
41 | endocrine-therapy | 1 |
42 | endpoint | 10,481 |
43 | endpoint-cardiac | 1 |
44 | endpoint-locoregional | 1 |
45 | endpoint-the | 2 |
46 | epi-regimen | 1 |
47 | falcigers | 1 |
48 | gs-01-934 | 2 |
49 | heart-rate/accelerometry | 1 |
50 | heartburn/regurgitation/dyspepsia | 1 |
51 | heat/alkali | 2 |
52 | hemipelvises | 1 |
53 | hemofiltration-hemodialysis | 2 |
54 | hgsil/carcinoma | 1 |
55 | hipertrigliceridemia | 1 |
56 | hiv-1-infection | 3 |
57 | hyercholesterolaemia | 1 |
58 | hyperoxalurias | 1 |
59 | idh1/mgmt | 1 |
60 | interest-for | 1 |
61 | leuokocytes | 1 |
62 | lipodystrophy-a | 1 |
63 | malignancies.this | 1 |
64 | microfil | 1 |
65 | mid-distraction | 1 |
66 | mortality/esrd | 1 |
67 | motordisturbance | 1 |
68 | n=2215 | 1 |
69 | n=3226 | 1 |
70 | neurrorhaphy | 1 |
71 | nonfunction | 20 |
72 | nonfunctionality | 2 |
73 | nu-onset | 3 |
74 | oftacrolimus | 1 |
75 | oral/intranasal | 1 |
76 | osteoarthris | 1 |
77 | outcme | 1 |
78 | outcome-baseline-adjusted | 2 |
79 | outcome-consistent | 1 |
80 | outcome-latch | 1 |
81 | outcome-measure | 1 |
82 | outcome-reduction | 1 |
83 | outcome-the | 2 |
84 | outcomes-the | 2 |
85 | outcomes-wheezing | 1 |
86 | outcomes.very | 1 |
87 | outcomes/statistical | 1 |
88 | outcomesthere | 1 |
89 | p-40 | 2 |
90 | pccc-pobh | 2 |
91 | pci-an | 1 |
92 | pci.further | 1 |
93 | photographer | 1 |
94 | production/respiration | 1 |
95 | protoalkaloid | 1 |
96 | protoalkaloidal | 1 |
97 | purpose—food | 1 |
98 | radiochemotherapy/surgery | 1 |
99 | rapid3-est | 1 |
100 | reattachments | 4 |
101 | risk-relevant | 1 |
102 | rs2472304 | 1 |
103 | scale-international | 11 |
104 | score≥210 | 1 |
105 | se/sp | 3 |
106 | ser89 | 3 |
107 | seromismatch | 1 |
108 | siv-induced | 2 |
109 | subjective/physiologic | 1 |
110 | tgcts | 7 |
111 | treatment.small | 1 |
112 | trial-endpoints | 1 |
113 | typus | 5 |
114 | udca+same | 2 |
115 | vaccination.the | 1 |
116 | videoscoring | 1 |
117 | ~260k | 1 |
118 | α=0.10 | 1 |
119 | ≥26-week | 1 |
1 | care. | 1 |
2 | α=0.10 | 1 |
3 | score≥210 | 1 |
4 | p-40 | 2 |
5 | rs2472304 | 1 |
6 | gs-01-934 | 2 |
7 | n=2215 | 1 |
8 | n=3226 | 1 |
9 | 1.656 | 1 |
10 | ser89 | 3 |
11 | lipodystrophy-a | 1 |
12 | hyercholesterolaemia | 1 |
13 | anti-lipidemia | 1 |
14 | hipertrigliceridemia | 1 |
15 | heartburn/regurgitation/dyspepsia | 1 |
16 | hgsil/carcinoma | 1 |
17 | aizawa | 3 |
18 | endpoint-cardiac | 1 |
19 | amine-specific | 2 |
20 | subjective/physiologic | 1 |
21 | 20-24°c | 1 |
22 | 205°c | 1 |
23 | siv-induced | 2 |
24 | care-delivered | 4 |
25 | care-based | 111 |
26 | outcome-baseline-adjusted | 2 |
27 | protoalkaloid | 1 |
28 | 40x/field | 1 |
29 | purpose—food | 1 |
30 | mortality/esrd | 1 |
31 | motordisturbance | 1 |
32 | characteristics-relevance | 1 |
33 | outcome-the | 2 |
34 | outcomes-the | 2 |
35 | endpoint-the | 2 |
36 | vaccination.the | 1 |
37 | e-scale | 4 |
38 | care-feasible | 2 |
39 | udca+same | 2 |
40 | outcme | 1 |
41 | outcomesthere | 1 |
42 | outcome-measure | 1 |
43 | 14mg/kg | 1 |
44 | videoscoring | 1 |
45 | outcomes-wheezing | 1 |
46 | pccc-pobh | 2 |
47 | outcome-latch | 1 |
48 | seromismatch | 1 |
49 | dysmenorrhoea-ii | 1 |
50 | heat/alkali | 2 |
51 | 48hpi | 1 |
52 | ~260k | 1 |
53 | ≥26-week | 1 |
54 | outcomes/statistical | 1 |
55 | protoalkaloidal | 1 |
56 | care/commercial | 1 |
57 | endpoint-locoregional | 1 |
58 | scale-international | 11 |
59 | -spinal-epidural | 1 |
60 | oral/intranasal | 1 |
61 | microfil | 1 |
62 | treatment.small | 1 |
63 | 3.1mg/ml | 1 |
64 | 32.10µg/ml | 1 |
65 | al-qadim | 2 |
66 | aldosteronism | 78 |
67 | pci-an | 1 |
68 | epi-regimen | 1 |
69 | 300μl/min | 1 |
70 | production/respiration | 1 |
71 | mid-distraction | 1 |
72 | hiv-1-infection | 3 |
73 | nonfunction | 20 |
74 | outcome-reduction | 1 |
75 | amine-nitro | 1 |
76 | se/sp | 3 |
77 | photographer | 1 |
78 | pci.further | 1 |
79 | 1hmrsi-dcemr | 2 |
80 | interest-for | 1 |
81 | 47s | 1 |
82 | hyperoxalurias | 1 |
83 | care-clinics | 1 |
84 | care.subjects/methods | 1 |
85 | cheiloplasties | 1 |
86 | hemipelvises | 1 |
87 | leuokocytes | 1 |
88 | malignancies.this | 1 |
89 | osteoarthris | 1 |
90 | hemofiltration-hemodialysis | 2 |
91 | falcigers | 1 |
92 | tgcts | 7 |
93 | care.participants | 1 |
94 | reattachments | 4 |
95 | derailments | 1 |
96 | trial-endpoints | 1 |
97 | aminocatalysts | 1 |
98 | care-plus | 1 |
99 | oftacrolimus | 1 |
100 | typus | 5 |
101 | au-onset | 1 |
102 | nu-onset | 3 |
103 | idh1/mgmt | 1 |
104 | care-relevant | 9 |
105 | risk-relevant | 1 |
106 | care–relevant | 2 |
107 | care—relevant | 1 |
108 | antibacterial-agent | 1 |
109 | caregiver/parent | 1 |
110 | outcome-consistent | 1 |
111 | end-point | 1,082 |
112 | endpoint | 10,481 |
113 | rapid3-est | 1 |
114 | neurrorhaphy | 1 |
115 | endocrine-therapy | 1 |
116 | radiochemotherapy/surgery | 1 |
117 | outcomes.very | 1 |
118 | heart-rate/accelerometry | 1 |
119 | nonfunctionality | 2 |